The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.

This communication highlights the development of a nicotinamide series of histone deacetylase inhibitors within the benzamide structural class. Extensive exploration around the nicotinamide core led to the discovery of a class I selective HDAC inhibitor that possesses excellent intrinsic and cell-based potency, acceptable ancillary pharmacology, favorable pharmacokinetics, sustained pharmacodynamics in vitro, and achieves in vivo efficacy in an HCT116 xenograft model.

[1]  O. Wiest,et al.  Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. , 2005, Journal of medicinal chemistry.

[2]  F. Dequiedt,et al.  Subtype selective substrates for histone deacetylases. , 2004, Journal of medicinal chemistry.

[3]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[5]  Rachel Jones,et al.  Behavioural genetics: Worms gang up on bacteria , 2002, Nature Reviews Genetics.

[6]  A. Wolffe,et al.  Chromatin organisation and human disease , 2000 .

[7]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[8]  A. Hagenbeek,et al.  Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia. , 1993, Cancer research.

[9]  J. R. Somoza,et al.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.

[10]  Gordon M. Crippen,et al.  Distance Geometry and Molecular Conformation , 1988 .

[11]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[12]  G. Whitesides,et al.  Molecular Self-Assembly through Hydrogen Bonding: Aggregation of Five Molecules To Form a Discrete Supramolecular Structure , 1993 .

[13]  T. Halgren.  MMFF VI. MMFF94s option for energy minimization studies , 1999, J. Comput. Chem..

[14]  C. Maroun,et al.  Histone deacetylase inhibitors: latest developments, trends and prospects. , 2005, Current medicinal chemistry. Anti-cancer agents.

[15]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[16]  A. Ardizzoni,et al.  In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. , 2005, Oncology research.

[17]  T. Suzuki,et al.  Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. , 1999, Journal of medicinal chemistry.

[18]  P. Lorusso,et al.  Preclinical pharmacokinetic, antitumor and toxicity studies with CL-994 (N-acetyldinaline) , 2004, Investigational New Drugs.

[19]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[20]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[21]  Tony Kouzarides,et al.  Acetylation: a regulatory modification to rival phosphorylation? , 2000, The EMBO journal.

[22]  C. Monneret,et al.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[23]  Thomas A. Miller.  Patent status of histone deacetylase inhibitors , 2004 .

[24]  P. Marks,et al.  Histone deacetylase inhibitors: from target to clinical trials , 2002, Expert opinion on investigational drugs.

[25]  A. Bird,et al.  Histone deacetylases: silencers for hire. , 2000, Trends in biochemical sciences.

[26]  R Holliday,et al.  The inheritance of epigenetic defects. , 1987, Science.

[27]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[28]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Feinberg,et al.  Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.

[30]  P. Marks,et al.  Inhibitors of histone deacetylase are potentially effective anticancer agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  K. Glaser,et al.  Histone deacetylase inhibitors: the Abbott experience. , 2003, Current medicinal chemistry.

[32]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[33]  Andras Fiser,et al.  Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.

[34]  S. Bates,et al.  MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. , 2002, Cancer research.

[35]  David M. Webster,et al.  Protein structure prediction : methods and protocols , 2000 .

[36]  P. Liberator,et al.  Histone deacetylase: a target for antiproliferative and antiprotozoal agents. , 2001, Current medicinal chemistry.

[37]  Stuart L Schreiber,et al.  Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. , 2002, Chemistry & biology.

[38]  V. Richon,et al.  Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.